 | • レポートコード：GIR-107A12331 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、乳がん用HER-2標的薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。乳がん用HER-2標的薬の種類別市場規模（トラスツズマブ、ペルツズマブ、ラパチニブ、ネラチニブ、トラスツズマブエムタンシン、ピロチニブ、その他）、用途別市場規模（病院、クリニック、ドラッグセンター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・乳がん用HER-2標的薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Roche、Chugai Pharmaceutical、GlaxoSmithKline、Novartis、Pfizer、CANbridge、Puma Biotechnology、Hengrui Medicine、Beacon Pharmaceuticals Limited、Hetero Drugs ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：トラスツズマブ、ペルツズマブ、ラパチニブ、ネラチニブ、トラスツズマブエムタンシン、ピロチニブ、その他 ・用途別分析2016年-2026年：病院、クリニック、ドラッグセンター、その他 ・乳がん用HER-2標的薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・乳がん用HER-2標的薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・乳がん用HER-2標的薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・乳がん用HER-2標的薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・乳がん用HER-2標的薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The HER-2 Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global HER-2 Targeted Drugs for Breast Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global HER-2 Targeted Drugs for Breast Cancer market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
HER-2 Targeted Drugs for Breast Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Other
Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other
Market segment by players, this report covers
Roche
Chugai Pharmaceutical
GlaxoSmithKline
Novartis
Pfizer
CANbridge
Puma Biotechnology
Hengrui Medicine
Beacon Pharmaceuticals Limited
Hetero Drugs
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of HER-2 Targeted Drugs for Breast Cancer
1.2 Classification of HER-2 Targeted Drugs for Breast Cancer by Type
1.2.1 Overview: Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2020
1.2.3 Trastuzumab
1.2.4 Pertuzumab
1.2.5 Lapatinib
1.2.6 Neratinib
1.2.7 Trastuzumab Emtansine
1.2.8 Pyrotinib
1.2.9 Other
1.3 Global HER-2 Targeted Drugs for Breast Cancer Market by Application
1.3.1 Overview: Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global HER-2 Targeted Drugs for Breast Cancer Market Size & Forecast
1.5 Global HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast by Region
1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region, (2016-2021)
1.5.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.6 South America HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 HER-2 Targeted Drugs for Breast Cancer Market Drivers
1.6.2 HER-2 Targeted Drugs for Breast Cancer Market Restraints
1.6.3 HER-2 Targeted Drugs for Breast Cancer Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.1.4 Roche HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Chugai Pharmaceutical
2.2.1 Chugai Pharmaceutical Details
2.2.2 Chugai Pharmaceutical Major Business
2.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.2.4 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Chugai Pharmaceutical Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.3.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.4.4 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.5.4 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 CANbridge
2.6.1 CANbridge Details
2.6.2 CANbridge Major Business
2.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.6.4 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 CANbridge Recent Developments and Future Plans
2.7 Puma Biotechnology
2.7.1 Puma Biotechnology Details
2.7.2 Puma Biotechnology Major Business
2.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.7.4 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Puma Biotechnology Recent Developments and Future Plans
2.8 Hengrui Medicine
2.8.1 Hengrui Medicine Details
2.8.2 Hengrui Medicine Major Business
2.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.8.4 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Hengrui Medicine Recent Developments and Future Plans
2.9 Beacon Pharmaceuticals Limited
2.9.1 Beacon Pharmaceuticals Limited Details
2.9.2 Beacon Pharmaceuticals Limited Major Business
2.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.9.4 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Beacon Pharmaceuticals Limited Recent Developments and Future Plans
2.10 Hetero Drugs
2.10.1 Hetero Drugs Details
2.10.2 Hetero Drugs Major Business
2.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.10.4 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Hetero Drugs Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 HER-2 Targeted Drugs for Breast Cancer Players Market Share
3.2.2 Top 10 HER-2 Targeted Drugs for Breast Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 HER-2 Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2016-2021)
5.2 HER-2 Targeted Drugs for Breast Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
6.2 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
6.3.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
6.3.2 United States HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
7.2 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country
7.3.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
7.3.2 Germany HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.3 France HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region
8.3.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2016-2026)
8.3.2 China HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.5 India HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
9.2 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
9.3 South America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
9.3.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
9.3.2 Brazil HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country
10.3.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
10.3.2 Turkey HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market HER-2 Targeted Drugs for Breast Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) by Region (2016-2021)
Table 5. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region (2021-2026)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 9. Roche HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Chugai Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 11. Chugai Pharmaceutical Major Business
Table 12. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 13. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 17. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 21. Novartis HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Pfizer Corporate Information, Head Office, and Major Competitors
Table 23. Pfizer Major Business
Table 24. Pfizer HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 25. Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. CANbridge Corporate Information, Head Office, and Major Competitors
Table 27. CANbridge Major Business
Table 28. CANbridge HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 29. CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Puma Biotechnology Corporate Information, Head Office, and Major Competitors
Table 31. Puma Biotechnology Major Business
Table 32. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 33. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Hengrui Medicine Corporate Information, Head Office, and Major Competitors
Table 35. Hengrui Medicine Major Business
Table 36. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 37. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Beacon Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors
Table 39. Beacon Pharmaceuticals Limited Major Business
Table 40. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 41. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Hetero Drugs Corporate Information, Head Office, and Major Competitors
Table 43. Hetero Drugs Major Business
Table 44. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 45. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) by Players (2019-2021)
Table 47. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Players (2019-2021)
Table 48. Breakdown of HER-2 Targeted Drugs for Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. HER-2 Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided
Table 50. HER-2 Targeted Drugs for Breast Cancer Mergers & Acquisitions in the Past Five Years
Table 51. HER-2 Targeted Drugs for Breast Cancer New Entrants and Expansion Plans
Table 52. Global HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) by Type (2016-2021)
Table 53. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Type (2016-2021)
Table 54. Global HER-2 Targeted Drugs for Breast Cancer Revenue Forecast by Type (2021-2026)
Table 55. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2021)
Table 56. Global HER-2 Targeted Drugs for Breast Cancer Revenue Forecast by Application (2021-2026)
Table 57. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 58. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 59. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 60. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 61. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 62. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2021-2026) & (USD Million)
Table 75. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 76. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 77. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 78. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 79. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 80. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. HER-2 Targeted Drugs for Breast Cancer Picture
Figure 2. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2020
Figure 3. Trastuzumab
Figure 4. Pertuzumab
Figure 5. Lapatinib
Figure 6. Neratinib
Figure 7. Trastuzumab Emtansine
Figure 8. Pyrotinib
Figure 9. Other
Figure 10. HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application in 2020
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Drug Center Picture
Figure 14. Other Picture
Figure 15. Global HER-2 Targeted Drugs for Breast Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global HER-2 Targeted Drugs for Breast Cancer Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region (2016-2026)
Figure 18. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region in 2020
Figure 19. North America HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. HER-2 Targeted Drugs for Breast Cancer Market Drivers
Figure 25. HER-2 Targeted Drugs for Breast Cancer Market Restraints
Figure 26. HER-2 Targeted Drugs for Breast Cancer Market Trends
Figure 27. Roche Recent Developments and Future Plans
Figure 28. Chugai Pharmaceutical Recent Developments and Future Plans
Figure 29. GlaxoSmithKline Recent Developments and Future Plans
Figure 30. Novartis Recent Developments and Future Plans
Figure 31. Pfizer Recent Developments and Future Plans
Figure 32. CANbridge Recent Developments and Future Plans
Figure 33. Puma Biotechnology Recent Developments and Future Plans
Figure 34. Hengrui Medicine Recent Developments and Future Plans
Figure 35. Beacon Pharmaceuticals Limited Recent Developments and Future Plans
Figure 36. Hetero Drugs Recent Developments and Future Plans
Figure 37. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Players in 2020
Figure 38. HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 39. Global Top 3 Players HER-2 Targeted Drugs for Breast Cancer Revenue Market Share in 2020
Figure 40. Global Top 10 Players HER-2 Targeted Drugs for Breast Cancer Revenue Market Share in 2020
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 42. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Type in 2020
Figure 43. Global HER-2 Targeted Drugs for Breast Cancer Market Share Forecast by Type (2021-2026)
Figure 44. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Application in 2020
Figure 45. Global HER-2 Targeted Drugs for Breast Cancer Market Share Forecast by Application (2021-2026)
Figure 46. North America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 47. North America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 48. North America HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 49. United States HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Canada HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Mexico HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Europe HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 53. Europe HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 54. Europe HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 55. Germany HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. France HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. United Kingdom HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Russia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Italy HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 61. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region (2016-2026)
Figure 63. China HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Japan HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South Korea HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. India HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Australia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 70. South America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 71. South America HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 72. Brazil HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2016-2026)
Figure 75. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2016-2026)
Figure 76. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 77. Turkey HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. UAE HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source
世界の乳がん用VEGF標的薬市場 2021：企業別、地域別、種類・用途別 The VEGF Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…- 世界の乳がん用ER標的薬市場 2021：企業別、地域別、種類・用途別 The ER Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
- 世界の乳がん治療薬市場 2021：企業別、地域別、種類・用途別 The Breast Cancer Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界の乳がん治療薬市場 2021：企業別、地域別、種類・用途別 The Breast Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…
- 世界の乳がん用内分泌療法薬市場 2021：企業別、地域別、種類・用途別 The Endocrine Therapy Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…